74 completed, 24 unknown, 12 terminated, 7 recruiting. 48 Phase 2, 38 Phase 1, 19 Phase 3, 7 Phase 4, 6 Not applicable.
Follow Leukemia, Promyelocytic, Acute: new trials by email Literature Review of Leukemia, Promyelocytic, Acute trials Research Report on Leukemia, Promyelocytic, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice Bone marrow or peripheral blood withdrawal for test comparison - Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 75 | 2027-01-01 | 2026-10-09 |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-20 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment Unaided Review First, Then AI-Assisted Review, AI-Assisted Review First, Then Unaided Review - Acute Promyelocytic Leukemia (APL), Acute Myeloid Leukaemia (AML) | Not applicable | Completed | Harvard Medical School (HMS and HSDM) | 10 | 2025-09-09 | 2025-10-31 |
| Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia Venetoclax, All-trans retinoic acid, Arsenic Trioxide (ATO) - Acute Promyelocytic Leukemia (APL) | Not applicable | Active not recruiting | Anhui Medical University | 28 | 2025-07-01 | 2025-09-23 |
| Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state - Acute Promyelocytic Leukemia (APL) | Phase 1 | Completed | SDK Therapeutics, Inc. | 12 | 2025-03-11 | 2025-11-18 |
| Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia Realgar-Indigo Naturalis Formulation - Acute Promyelocytic Leukemia (APL) | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 115 | 2023-10-20 | 2025-05-30 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Optimum Induction Therapy of Low-risk APL Etoposide, Daunorubicin - Acute Promyelocytic Leukemia, Induction Therapy | Not applicable | Unknown | Peking University People's Hospital | 74 | 2023-01-01 | 2024-05-10 |
| Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL Arsenic trioxide, all-trans retinoic acid - Promyelocytic Leukemia | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2022-07-01 | 2022-10-26 |
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia SY-2101, Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 1 | Suspended | Syros Pharmaceuticals | 16 | 2021-09-17 | 2024-01-23 |
| RWE of 1st Line Treatment With ATO/ATRA for Adult APL Evaluation of first line treatment with ATO/ATRA outcome - Promyelocytic Leukemia, Adult Acute | Recruiting | Grupo Argentino de Tratamiento de la Leucemia Aguda | 50 | 2021-03-01 | 2024-01-09 | |
| Frontline Oral Arsenic Trioxide for APL Oral Arsenic Trioxide Formulation - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 100 | 2021-01-01 | 2025-06-12 |
| PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18 - Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 77 | 2020-07-15 | 2026-10-13 |
| Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia Arsenic Trioxide - Acute Promyelocytic Leukemia | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 100 | 2020-04-14 | 2022-01-04 | |
| The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project Acute Promyelocytic Leukemia | Unknown | The University of Hong Kong | 1000 | 2020-02-02 | 2022-10-04 | |
| Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid - Acute Promyelocytic Leukaemia | Phase 3 | Unknown | Peking University People's Hospital | 109 | 2019-12-01 | 2019-11-29 |
| Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Mylotarg, Arsenic Trioxide, All-trans retinoic acid - Acute Promyelocytic Leukemia | Phase 2 | Recruiting | Associazione Italiana Ematologia Oncologia Pediatrica | 89 | 2019-10-09 | 2024-04-15 |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Oral arsenic Trioxide, ATRA and ascorbic acid - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 60 | 2018-08-15 | 2022-10-04 |
Showing 20 of 130. Sign in to see all of them.
Leukemia, Myeloid, Acute (62) · Leukemia (46) · Leukemia, Myelomonocytic, Acute (37) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Leukemia, Erythroblastic, Acute (29) · Leukemia, Megakaryoblastic, Acute (28) · Leukemia, Monocytic, Acute (28) · Congenital Abnormalities (26) · Blast Crisis (23) · Myelodysplastic Syndromes (21) · Leukemia, Myelomonocytic, Chronic (16) · Leukemia, Myeloid, Accelerated Phase (15) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Myeloproliferative Disorders (14)
Hemic and Lymphatic Diseases (130) · Leukemia, Myeloid (130) · Neoplasms by Histologic Type (130) · Hematologic Diseases (129) · Neoplasms (128) · Leukemia (84) · Leukemia, Myeloid, Acute (68) · Bone Marrow Diseases (50) · Disease Attributes (40) · Pathologic Processes (40) · Pathological Conditions, Signs and Symptoms (40) · Chronic Disease (37) · Immune System Diseases (34) · Immunoproliferative Disorders (34) · Leukemia, Lymphoid (34)
Arsenic Trioxide (27) · Tretinoin (27) · Cytarabine (20) · Cyclophosphamide (14) · Idarubicin (13) · Methotrexate (13) · Busulfan (11) · Filgrastim (10) · Etoposide (8) · Daunorubicin (7) · Gemtuzumab (7) · Mercaptopurine (7) · Peripheral Blood Stem Cell Transplantation (7) · fludarabine phosphate (7) · Radiotherapy (6)
National Cancer Institute (NCI) (19) · Gruppo Italiano Malattie EMatologiche dell'Adulto (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Memorial Sloan Kettering Cancer Center (6) · M.D. Anderson Cancer Center (5) · Case Comprehensive Cancer Center (4) · Children's Oncology Group (4) · Alliance for Clinical Trials in Oncology (3) · Fred Hutchinson Cancer Center (3) · Northwestern University (3) · PETHEMA Foundation (3) · The University of Hong Kong (3) · University of Maryland, Baltimore (3) · Associazione Italiana Ematologia Oncologia Pediatrica (2) · Barbara Ann Karmanos Cancer Institute (2)
United States (84) · Italy (12) · Germany (11) · China (7) · France (6) · Spain (6) · Netherlands (5) · Canada (4) · Hong Kong (4) · Belgium (3) · Austria (2) · Czechia (2) · Denmark (2) · India (2) · Mexico (2)
Jorge Cortes (4) · Judith E. Karp, MD (4) · Brenda W. Cooper, MD (3) · Olatoyosi Odenike (3) · Peter Maslak, MD (3) · Asad Bashey, MD, PhD (2) · Barry R. Meisenberg, MD (2) · Farhad Ravandi-Kashani, MD (2) · Jason N. Berman, MD (2) · Jorge Cortes, MD (2) · Joseph G. Jurcic, MD (2) · Martin S. Tallman, MD (2) · Sanz Miguel Angel, Dr (2) · Steven Gore (2) · Aaron Schimmer, MD (1)
PMID 20705755, PMID 23841729, PMID 27400939, PMID 20644121, PMID 21385856, PMID 22715121, PMID 10438706, PMID 10552940, PMID 11122141, PMID 11559723, PMID 12393590, PMID 17116939, PMID 1732003, PMID 17562873, PMID 17640728, PMID 189506, PMID 19225113, PMID 19289999, PMID 19414681, PMID 19741727, PMID 19794082, PMID 19797519, PMID 19804455, PMID 20018913, PMID 20038732, PMID 20393132, PMID 20952518, PMID 21148082, PMID 21751984, PMID 21898784, PMID 21998212, PMID 22801963, PMID 23443507, PMID 24127444, PMID 24178622, PMID 24528179, PMID 25085357, PMID 25245446, PMID 25470713, PMID 25528350, PMID 25975975, PMID 26577691, PMID 26853648, PMID 27198129, PMID 27374466, PMID 28003274, PMID 28584252, PMID 29034366, PMID 29196412, PMID 29579321
P30CA006973 (5), U01CA062461 (4), P30CA016672 (3), P30CA043703 (3), U10CA031946 (3), 2025 (2), N01CM62201 (2), P30CA014599 (2), P30CA015704 (2), P30CA016058 (2), P30CA022453 (2), U01CA076576 (2), U10CA032102 (2), 2009 (1), 2017 (1)